Assembly Biosciences Future Growth

Future criteria checks 0/6

Assembly Biosciences's earnings are forecast to decline at 10.4% per annum while its annual revenue is expected to grow at 58.5% per year. EPS is expected to decline by 5.8% per annum.

Key information

-10.4%

Earnings growth rate

-5.8%

EPS growth rate

Biotechs earnings growth	30.9%
Revenue growth rate	58.5%
Future return on equity	n/a
Analyst coverage	Low
Last updated	01 Apr 2024

Recent future growth updates

No updates

Recent updates

Earnings and Revenue Growth Forecasts

BST:V7B - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	53	-97	N/A	N/A	2
12/31/2025	N/A	-89	N/A	N/A	2
12/31/2024	N/A	-82	N/A	N/A	2
12/31/2023	7	-61	22	23	N/A
9/30/2023	N/A	-73	-70	-70	N/A
6/30/2023	N/A	-81	-76	-76	N/A
3/31/2023	N/A	-89	-80	-80	N/A
12/31/2022	N/A	-93	-85	-84	N/A
9/30/2022	N/A	-131	-85	-85	N/A
6/30/2022	6	-127	-84	-84	N/A
3/31/2022	6	-126	-88	-88	N/A
12/31/2021	6	-130	-96	-93	N/A
9/30/2021	7	-109	-104	-99	N/A
6/30/2021	36	-94	-75	-70	N/A
3/31/2021	75	-63	-76	-71	N/A
12/31/2020	79	-62	-65	-63	N/A
9/30/2020	83	-50	-59	-58	N/A
6/30/2020	52	-71	-88	-87	N/A
3/31/2020	16	-97	-85	-85	N/A
12/31/2019	16	-98	-86	-84	N/A
9/30/2019	15	-97	-82	-80	N/A
6/30/2019	15	-93	-80	-78	N/A
3/31/2019	15	-102	-75	-73	N/A
12/31/2018	15	-91	-65	-65	N/A
9/30/2018	14	-68	-58	-58	N/A
6/30/2018	13	-58	-53	-52	N/A
3/31/2018	12	-45	-49	-49	N/A
12/31/2017	9	-43	1	2	N/A
9/30/2017	6	-51	N/A	1	N/A
6/30/2017	3	-51	N/A	4	N/A
3/31/2017	1	-47	N/A	9	N/A
12/31/2016	N/A	-44	N/A	-35	N/A
9/30/2016	N/A	-40	N/A	-29	N/A
6/30/2016	N/A	-36	N/A	-27	N/A
3/31/2016	N/A	-32	N/A	-24	N/A
12/31/2015	N/A	-28	N/A	-19	N/A
9/30/2015	N/A	-27	N/A	-17	N/A
6/30/2015	N/A	-31	N/A	-16	N/A
3/31/2015	N/A	-27	N/A	-13	N/A
12/31/2014	N/A	-24	N/A	-15	N/A
9/30/2014	N/A	-24	N/A	-17	N/A
6/30/2014	N/A	-17	N/A	-18	N/A
3/31/2014	N/A	-20	N/A	-19	N/A
12/31/2013	N/A	-19	N/A	-18	N/A
9/30/2013	N/A	-17	N/A	-15	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: V7B is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: V7B is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: V7B is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: V7B is forecast to have no revenue next year.

High Growth Revenue: V7B is forecast to have no revenue next year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if V7B's Return on Equity is forecast to be high in 3 years time

Assembly Biosciences Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Recent updates

New minor risk - Insider selling

Assembly Biosciences, Inc., Annual General Meeting, May 29, 2024

Assembly Biosciences, Inc. Appoints Tomas Cihlar to Serve on the Board

New major risk - Revenue and earnings growth

Assembly Biosciences, Inc. Appoints Anuj Gaggar as Chief Medical Officer

Assembly Biosciences Receives Non-Compliance Notice from Nasdaq

Assembly Biosciences, Inc. to Present Pipeline Progress in HBV and HDV at the 2023 International HBV Meeting

New major risk - Revenue and earnings growth

Assembly Biosciences, Inc. Nominates First Herpesvirus Development Candidate ABI-5366, a Long Acting HSV-2 Helicase Inhibitor Targeting High-Recurrence Genital Herpes

High number of new directors

Assembly Biosciences, Inc. Announces Promising Interim Results from Two Clinical Trials Evaluating Highly Potent Next-Generation Core Inhibitor Candidates ABI-H3733 and ABI-4334

High number of new directors

Assembly Biosciences, Inc. Doses First Subject in Phase 1a Clinical Trial to Evaluate Safety, Tolerability and Pharmacokinetic Profile of Investigational Next Generation Core Inhibitor ABI-4334

Assembly Biosciences, Inc. Presents New Data at AASLD Liver Meeting Highlighting Breadth of Virology Portfolio and Potential of Next-Generation Core Inhibitors in HBV

High number of new directors

Assembly Biosciences, Inc. Announces Executive Changes

Assembly Biosciences, Inc. Announces Management Appointments

Assembly Biosciences, Inc. Announces Executive Changes

Assembly Biosciences, Inc. to Introduce New Small Molecule Liver-Focused Interferon-a Receptor Agonist Research Program

Assembly Biosciences Inc. Initiates Phase 1B Clinical Trial Evaluating Next Generation Core Inhibitor ABI-H3733 for the Treatment of Chronic Hepatitis B Virus Infection

High number of new directors

Assembly Biosciences, Inc., Annual General Meeting, May 25, 2022

High number of new directors

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

High number of new directors

High number of new directors

Assembly Biosciences, Inc.(NasdaqGS:ASMB) dropped from Russell Microcap Growth Index

Assembly Biosciences Presents Data from HBV Core Inhibitor Programs At the International Liver Congress™ EASL 2021

CFO & Principal Accounting Officer Thomas Russo has left the company

Full year 2020 earnings released: US$1.75 loss per share (vs US$3.72 loss in FY 2019)

Revenue misses expectations

Assembly Biosciences Updates Pipeline Strategy, Focusing on Finite and Curative Therapies for Chronic Hepatitis B Virus Infection

New 90-day low: €4.12

New 90-day high: €5.40

Assembly Biosciences, Inc. Announces Board Changes, Effective December 31, 2020

Assembly Biosciences, Inc. Appoints Nicole S. White as Senior Vice President of Pharmaceutical Development and Manufacturing

New 90-day low: €4.20

Third quarter 2020 earnings released: US$0.094 loss per share

Revenue beats expectations

Assembly Bio Provides Update on the Ongoing Phase 2 Extension Study of Vebicorvir in Patients with Chronic Hepatitis B Virus Infection

Assembly Biosciences, Inc. Announces HBV Core Inhibitor Research and Development Program

New 90-day low: €12.60

New 90-day low: €13.80

New 90-day low - €16.50

First half earnings released

New 90-day high - €23.40

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies